New Drug Offers Hope for FAP by Targeting 'Undruggable' Cancer Driver

CAMBRIDGE, Mass. – March 05, 2026 – For patients with Familial Adenomatous Polyposis (FAP), a rare and devastating genetic disorder, the path of life is often dictated by a near-certainty of cancer and the life-altering surgeries to prevent it. Now, early clinical data for an investigational drug is offering a glimmer of hope that this path could be fundamentally changed.

Parabilis Medicines, a clinical-stage biopharmaceutical company, announced promising preliminary data for its drug zolucatetide. The findings, presented at the 11th Biennial Meeting of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT), suggest that targeting the core genetic driver of the disease is not only possible, but could be transformative for patients.

A Potential Turning Point for a Devastating Disease

FAP is caused by an inherited mutation in the APC gene, leading to the growth of hundreds or even thousands of precancerous polyps throughout the colon. Without intervention, progression to colorectal cancer is virtually inevitable, often at a young age. The current standard of care is not a drug, but a prophylactic colectomy—the surgical removal of the colon—a major procedure that carries lifelong consequences for a patient's quality of life.

Even after surgery, patients are not free from the disease's grasp. They face a lifetime of surveillance for new growths in the remaining rectum or upper gastrointestinal tract, such as the duodenum. It is here that the early data for zolucatetide has generated significant excitement.

In the company’s ongoing Phase 1/2 trial, a single FAP patient treated with zolucatetide showed a substantial reduction in both the number and size of duodenal polyps after 60 weeks. This improvement was significant enough to downstage the patient’s disease from Spigelman stage II to the less severe stage I. The same patient, who also had an associated desmoid tumor—an aggressive, non-cancerous growth common in FAP—experienced a 52.2% reduction in the tumor's diameter. Critically, no serious treatment-related side effects were reported.

“Patients with FAP face a lifetime of intensive surveillance and often prophylactic colectomy, yet there are no approved therapies,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO and President of Parabilis Medicines, in a statement. “Our goal is to move beyond managing polyp burden and toward altering the course of disease for patients suffering from FAP.”

Cracking the Code of an 'Undruggable' Target

The scientific achievement behind zolucatetide is as significant as its clinical potential. The drug is the first to directly inhibit the interaction between two proteins, β-catenin and TCF, which sit at the heart of the Wnt signaling pathway. In FAP, the mutated APC gene causes β-catenin to accumulate and drive the uncontrolled cell growth that forms polyps.

For decades, this specific β-catenin:TCF interaction has been considered “undruggable” by the scientific community. The proteins bind together across a large, flat surface, lacking the distinct pockets that traditional small-molecule drugs typically latch onto. Furthermore, as an intracellular target, any potential drug must be able to effectively penetrate the cell membrane to work.

Parabilis Medicines overcame this long-standing challenge with its proprietary Helicon™ peptide platform. This technology allows the company to design a new class of stabilized, cell-penetrating peptides that can mimic protein surfaces. Zolucatetide was designed to act as a competitive inhibitor, essentially tricking β-catenin into binding with it instead of TCF. This action shuts down the aberrant growth signal at its source, a feat many believed was impossible.

Supporting the clinical observations, preclinical studies in mouse models of FAP confirmed that zolucatetide reduced polyp formation at exposure levels relevant to the human trial, reinforcing the drug’s mechanism of action.

Beyond FAP: A Broader Horizon for Wnt-Driven Cancers

The implications of successfully targeting the Wnt/β-catenin pathway extend far beyond the estimated 34,000 FAP patients in the United States. This pathway is a central oncogenic driver in a vast spectrum of both rare and common cancers, implicated in millions of cases annually.

Parabilis is strategically exploring zolucatetide's potential across this landscape. The drug has already received a Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of desmoid tumors, a significant regulatory milestone that acknowledges the drug's potential to address a serious unmet need and aims to expedite its development.

Other Wnt/β-catenin-driven cancers in the company's sights include adamantinomatous craniopharyngioma (ACP), a rare and difficult-to-treat brain tumor, and hepatocellular carcinoma (HCC), the most common form of liver cancer. The ability to shut down this fundamental cancer-driving pathway could provide a powerful new weapon for oncologists across multiple disciplines.

The Road Ahead: Cautious Optimism and Future Trials

While the initial results are highly encouraging, experts urge cautious optimism. The remarkable data comes from a single patient in an ongoing Phase 1/2 trial, and the findings will need to be replicated in a larger patient population to confirm the drug's efficacy and long-term safety. Chronic inhibition of a pathway as fundamental as Wnt, even with a targeted approach, requires careful and extended study.

The medical community will be watching closely as Parabilis moves forward. The company has already dosed more than 150 patients in its ongoing trial across various tumor types and plans to share additional data readouts in 2026. These future results will be critical in determining whether zolucatetide can fulfill its promise and become a truly transformative therapy, not only offering a non-surgical option for FAP but also ushering in a new era of treatment for a wide range of difficult-to-treat cancers.